Lornoxicam
As of the edition of 20 October 2026, Lornoxicam is a small molecule: marketed, first approved in 2009 (BR); acts on PTGS1 and PTGS2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2009
- Kind
- Small molecule
- Brand name
- Xefo
- First approved
- 14 December 2009 (BR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- BIOLAB SANUS FARMACĂUTICA LTDA
- Registered trials
- 16, 2 stopped early
- Disease areas
- Cancer; Immune system; Blood and lymph; Heart and blood vessels; Skin and connective tissue; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 2 | 8 | 4 | 1 | 2 |
| Phase 3 | 3 | 2 | 0 | 0 |
| Phase 4 | 3 | 2 | 0 | 0 |
| All trials | 16 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pozen | Lead sponsor of trials | 2005 to now |